SOHM

Executive Summary

SOHM Inc., founded in 2003 and headquartered in Chino, California, is a diversified biotechnology and pharmaceutical company. It develops, manufactures, and distributes generic pharmaceuticals, nutraceuticals, and cosmeceuticals, while also advancing a patented gene editing technology for novel treatments. The company operates through multiple business units, including generic drugs, nutraceuticals, a biotech division, and contract development and manufacturing (CDMO) services. SOHM leverages its manufacturing capabilities and research to address both immediate market needs via generics and long-term innovation via gene editing. Despite being private with limited public disclosures, the company's diversified approach and focus on niche products position it for steady growth. Key strengths include an established operational footprint and potential for proprietary treatments. However, risks include reliance on generic margins and an unproven gene editing pipeline. Overall, SOHM represents a small-cap biopharma with modest near-term upside potential.

Upcoming Catalysts (preview)

• Q3 2026Launch of a high-margin generic drug for a chronic condition60% success
• TBDPartnership or licensing deal for gene editing platform30% success
• Q4 2026FDA approval of a new abbreviated new drug application (ANDA)50% success